The PALLAS trial demonstrated a lower incidence of neutropenia with CDK4/6i and aromatase inhibitor as adjuvant treatment in patients with BMI ≥ 25 without affecting treatment efficacy [10]. This evidence concerns the gene CYP19A1 and Decreased total neutrophil count.